Proliferation signal inhibitor toxicities after thoracic transplantation

Bibliography

• Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335-40
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:7S-14S
   PubMed Web of Science ®Google Scholar
• Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998;30:2192-4
   PubMed Web of Science ®Google Scholar
• Schuler W, Sedrani R, Cottens S, SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42
   PubMed Web of Science ®Google Scholar
• Crowe A, Bruelisauer A, Duerr L, Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999;27:627-32
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services/U.S. Food and Drug Administration. Rapamune prescribing information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ [Accessed 12 March 2012]
   Google Scholar
• U.S. Department of Health and Human Services/U.S. Food and Drug Administration. Zortress prescribing information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ [Accessed 12 March 2012]
   Google Scholar
• U.S. Department of Health and Human Services/U.S. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors, and inducers. Available from: http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#classInhibit [Accessed 12 March 2012]
   Google Scholar
• Zuckermann A, Manito N, Epailly E, Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008;27:141-9
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Miller LW, Russell SD, Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6:1377-86
   PubMed Web of Science ®Google Scholar
• Valentine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 2007;26:557-64
   PubMed Web of Science ®Google Scholar
• Kauffman HM, Cherikh WS, Cheng Y, Maintenance immunosuppression with target of rapamycin inhibitors is associated with a reduced-incidence of de novo malignancies. Transplantation 2005;80:883-9
   PubMed Web of Science ®Google Scholar
• Chen F, Omasa M, Kondo N, Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation. Ann Thorac Surg 2009;87:e6-7
   PubMed Web of Science ®Google Scholar
• Morton JM, McLean C, Booth SS, Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant 2008;27:462-5
   PubMed Web of Science ®Google Scholar
• Potena L, Bianchi IG, Magnani G, Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study. Transplantation 2010;89:263-5
   PubMed Web of Science ®Google Scholar
• Potena L, Prestinenzi P, Bianchi IG, Cyclosporine lowering with everolimus or mycophenolate mofetil in heart transplant recipients: long-term follow-ip of the SHIRAKISS randomized, prospective study. J Heart Lung Transplant 2012;31:565-70
   PubMed Web of Science ®Google Scholar
• Gullestad L, Iversen M, Mortensen SA, Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010;89:864-72
   PubMed Web of Science ®Google Scholar
• Arora S, Gude E, Sigurdardottir V, Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate. J Heart Lung Transplant 2012;31:259-65
   PubMed Web of Science ®Google Scholar
• Zuckermann A, Keogh A, Crespo-Leiro MG, Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. Am J Transplant 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Balfour IC, Srun SW, Wood EG, Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant 2006;25:518-22
   PubMed Web of Science ®Google Scholar
• Vigano M, Dengler T, Mattei MF, Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized multicenter study. Transpl Infect Dis 2010;12:23-30
   PubMed Web of Science ®Google Scholar
• Fishman JA, Emery V, Freeman R, Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 2007;21:149-58
   PubMed Web of Science ®Google Scholar
• Hill JA, Hummel M, Starling RC, A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007;84:1436-42
   PubMed Web of Science ®Google Scholar
• Ross H, Kfoury AG, Van Balek A, Lower incidence of viral infections with everolimus versus MMF in de novo heart transplant recipients: 12 month analysis of a randomized multicenter study. J Heart Lung Transplant 2011;30:171s
   Web of Science ®Google Scholar
• Potena L, Bianchi IG, D'Agostino C, Everolimus treatment reduces the need for anti-CMV prophylaxis in de novo heart transplant recipients. J Heart Lung Transplant 2011;30:172s
   Web of Science ®Google Scholar
• Demopoulos L, Pollinsky M, Steele G, Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008;40:1407-10
   PubMed Web of Science ®Google Scholar
• Delgado JF, Manito N, Almenar L, Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study. Transpl Infect Dis 2011;13:136-44
   PubMed Web of Science ®Google Scholar
• Poglitsch M, Weichhart T, Hecking M, CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Transplant 2012;12:1458-68
   PubMed Web of Science ®Google Scholar
• Ferrer IR, Araki K, Ford ML. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011;11:654-9
   Google Scholar
• Araki K, Turner AP, Shaffer VO, mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-13
   PubMed Web of Science ®Google Scholar
• Azzola A, Havryk A, Chhajed P, Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004;77:275-80
   PubMed Web of Science ®Google Scholar
• Snell GI, Valentine VG, Vitulo P, Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006;6:169-77
   PubMed Web of Science ®Google Scholar
• Bhorade S, Ahya VN, Baz MA, Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med 2011;183:379-87
   PubMed Web of Science ®Google Scholar
• Groetzner J, Wittwer T, Kaczmarek I, Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006;81:355-60
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, Katznelson S, Laks H, Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7
   PubMed Web of Science ®Google Scholar
• Tenderich G, Fuchs U, Zittermann A, Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007;21:536-43
   PubMed Web of Science ®Google Scholar
• Pauly D, Starling R, Kobashigawa J, Heart transplant recipients treated with everolimus have less increase in intimal thickness vs. MMF, irrespective of lipid values. J Heart Lung Transplant 2011;30:57s
   Web of Science ®Google Scholar
• Kobashigawa J, Pauly D, Ross H, Reduction of cardiac allograft vasculopathy with everolimus over mycophenolate mofetil: intravascular ultrasound results of a randomized multicenter trial. J Heart Lung Transplant 2011;30:52S
   Web of Science ®Google Scholar
• Arora S, Ueland T, Wennerblom B, Effect of everolimus introduction on cardiac allograft vasculopathy-results of a randomized, multicenter trial. Transplantation 2011;92:235-43
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R, Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-58
   PubMed Web of Science ®Google Scholar
• Keogh A, Richardson M, Ruygrok P, Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110:2694-700
   PubMed Web of Science ®Google Scholar
• Mancini D, Pinney S, Burkhoff D, Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53
   PubMed Web of Science ®Google Scholar
• Raichlin E, Bae JH, Khalpey Z, Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007;116:2726-33
   PubMed Web of Science ®Google Scholar
• Topilsky Y, Hasin T, Raichlin E, Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation 2012;125:708-20
   PubMed Web of Science ®Google Scholar
• Epailly E, Albanell J, Andreassen A, Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions. Clin Transplant 2011;25:E475-86
   PubMed Web of Science ®Google Scholar
• Ahya VN, McShane PJ, Baz MA, Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation. J Heart Lung Transplant 2011;30:175-81
   PubMed Web of Science ®Google Scholar
• Dittrich E, Schmaldienst S, Soleiman A, Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004;17:215-20
   PubMed Web of Science ®Google Scholar
• Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004;78:1362-6
   PubMed Web of Science ®Google Scholar
• Straathof-Galema L, Wetzels JF, Dijkman HB, Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006;6:429-33
   PubMed Web of Science ®Google Scholar
• Laugharne M, Cross S, Richards S, Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines. Transplantation 2007;83:1635-8
   PubMed Web of Science ®Google Scholar
• Rodrigo E, Santos L, Pinera C, Early prediction of new-onset diabetes mellitus by fifth-day fasting plasma glucose, pulse pressure, and proteinuria. Transplant Proc 2011;43:2208-10
   PubMed Web of Science ®Google Scholar
• Lieberthal W, Fuhro R, Andry CC, Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281:F693-706
   PubMed Web of Science ®Google Scholar
• Chapman JR, Rangan GK. Why do patients develop proteinuria with sirolimus? Do we have the answer? Am J Kidney Dis 2010;55:213-16
   PubMed Web of Science ®Google Scholar
• Bertoni E, Bruschi M, Candiano G, Posttransplant proteinuria associated with everolimus. Transplant Proc 2009;41:1216-17
   PubMed Web of Science ®Google Scholar
• Oroszlan M, Bieri M, Ligeti N, Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 2010;23:125-32
   PubMed Web of Science ®Google Scholar
• Serkova N, Litt L, James TL, Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. J Pharmacol Exp Ther 1999;289:800-6
   PubMed Web of Science ®Google Scholar
• Aliabadi AZ, Mahr S, Dunkler D, Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 2008;86:1771-6
   PubMed Web of Science ®Google Scholar
• Stephany BR, Boumitri M, Budev M, Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease. J Heart Lung Transplant 2009;28:564-71
   PubMed Web of Science ®Google Scholar
• Raichlin E, Khalpey Z, Kremers W, Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 2007;84:467-74
   PubMed Web of Science ®Google Scholar
• Roman A, Ussetti P, Zurbano F, A retrospective 12-month study of conversion to everolimus in lung transplant recipients. Transplant Proc 2011;43:2693-8
   PubMed Web of Science ®Google Scholar
• Zuckermann A, Barten MJ. Surgical wound complications after heart transplantation. Transpl Int 2011;24:627-36
   PubMed Web of Science ®Google Scholar
• Zuckermann A, Arizon JM, Dong G, Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation. Transplantation 2011;92:594-600
   PubMed Web of Science ®Google Scholar
• Kondo T, Ishida Y. Molecular pathology of wound healing. Forensic Sci Int 2010;203:93-8
   PubMed Web of Science ®Google Scholar
• Cao W, Mohacsi P, Shorthouse R, Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995;59:390-5
   PubMed Web of Science ®Google Scholar
• Ekici Y, Emiroglu R, Ozdemir H, Effect of rapamycin on wound healing: an experimental study. Transplant Proc 2007;39:1201-3
   PubMed Web of Science ®Google Scholar
• Kahn D, Spearman CW, Mall A, The effect of rapamycin on the healing of the ureteric anastomosis and wound healing. Transplant Proc 2005;37:830-1
   PubMed Web of Science ®Google Scholar
• van der Vliet JA, Willems MC, de Man BM, Everolimus interveres with healing of experimental intestinal anastamoses. Transplantation 2006;82:1477-83
   PubMed Web of Science ®Google Scholar
• Lepelletier D, Perron S, Bizouarn P, Surgical-site infection after cardiac surgery: incidence, microbiology, and risk factors. Infect Control Hosp Epidemiol 2005;26:466-72
   PubMed Web of Science ®Google Scholar
• Carrier M, Perrault LP, Pellerin M, Sternal wound infection after heart transplantation: incidence and results with aggressive surgical treatment. Ann Thorac Surg 2001;72:719-23
   PubMed Web of Science ®Google Scholar
• Kuppahally S, Al-Khaldi A, Weisshaar D, Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006;6:986-92
   PubMed Web of Science ®Google Scholar
• Kshettry VR, Kroshus TJ, Hertz MI, Early and late airway complications after lung transplantation: incidence and management. Ann Thorac Surg 1997;63:1576-83
   PubMed Web of Science ®Google Scholar
• Groetzner J, Kur F, Spelsberg F, Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004;23:632-8
   PubMed Web of Science ®Google Scholar
• King-Biggs MB, Dunitz JM, Park SJ, Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003;75:1437-43
   PubMed Web of Science ®Google Scholar
• Dutly AE, Gaspert A, Inci I, The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses. Eur J Cardiothorac Surg 2003;24:154-8
   PubMed Web of Science ®Google Scholar
• Willems MC, van der Vliet JA, de Man BM, Persistent effects of everolimus on strength of experimental wounds in intestine and fascia. Wound Repair Regen 2010;18:98-104
   PubMed Web of Science ®Google Scholar
• Garrean S, Massad MG, Tshibaka M, Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005;19:698-703
   PubMed Web of Science ®Google Scholar
• Vlahakis NE, Rickman OB, Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 2004;79:541-5
   PubMed Web of Science ®Google Scholar
• Morelon E, Stern M, Israel-Biet D, Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001;72:787-90
   PubMed Web of Science ®Google Scholar
• Banerjee SK, Santhanakrishnan K, Tsui S, Cavitatory lung disease in thoracic transplant recipients receiving sirolimus. J Heart Lung Transplant 2012;31:548-51
   PubMed Web of Science ®Google Scholar
• Chhajed PN, Dickenmann M, Bubendorf L, Pattern of pulmonary complications associated with sirolimus. Resipration 2006;73:367-74
   PubMed Web of Science ®Google Scholar
• Howard L, Gopalan D, Griffiths M, Mahadexa R. Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest 2006;129:1718-21
   PubMed Web of Science ®Google Scholar
• Hamour IM, Mittal TK, Bell AD, Banner NR. Reversible sirolimus-associated pneumonitis after heart transplantation. J Heart Lung Transplant 2006;25:241-4
   PubMed Web of Science ®Google Scholar
• McWilliams TJ, Levvey BJ, Russell PA, Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 2003;22:210-13
   PubMed Web of Science ®Google Scholar
• Garcia-Luque A, Cordero E, Torello J, Sirolimus-associated pneumonitis in heart transplant recipients. Ann Pharmacother 2008;42:1143
   PubMed Web of Science ®Google Scholar
• Otton J, Hayward CS, Keogh AM, Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant 2009;28:104-6
   PubMed Web of Science ®Google Scholar
• Exposito V, Vazquez JA, Gomez-Roman JJ, Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 2008;27:797-800
   PubMed Web of Science ®Google Scholar
• Zuckermann A, Arizon J, Eisen H, Risk factors for pericardial and pleural effusions in heart transplant recipients exposed to everolimus, azathioprine, or MMF. J Heart Lung Transplant 2011;30:244s
   Google Scholar
• Ferrer IR, Araki K, Ford ML. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011;11:654-9
   Google Scholar
• Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 2007;19:162-72
   PubMed Web of Science ®Google Scholar